Divis Laboratories Ltd Analyst Rating
based on 27 analysts
33.33%
Buy
18.52%
Hold
48.15%
Sell
Based on 27 analysts offering long term price targets for Divis Laboratories Ltd. An average target of ₹5512.44
Source: S&P Global Market Intelligence
Divis Laboratories Ltd Share analysis
Divis Laboratories Ltd price forecast by 27 analysts
Downside of
High
₹6983
Target
₹5512.44
Low
₹3590
Divis Laboratories Ltd target price ₹5512.44, a slight downside of -7.01% compared to current price of ₹5951.7. According to 27 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:38.05%
Forecast
Actual
Including amortisation and stock based compensations
Divis Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:64.18%
Forecast
Actual
Source: S&P Global Market Intelligence
Divis Laboratories Ltd Performance
Day's Low
Day's High
₹5,928.25₹6,05552 Week's Low
52 Week's High
₹3,350₹6,285.45
| Returns % | |
| 1 Month Return | + 2.02 % |
| 3 Month Return | + 8.12 % |
| 1 Year Return | + 62.52 % |
| Market Stats | |
| Previous Close | ₹5,927.95 |
| Open | ₹5,950.00 |
| Volume | 3.59L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,57,368.45Cr |
Divis Laboratories Ltd Key Statistics
| P/E Ratio | 85.73 |
| PEG Ratio | 4.52 |
| Market Cap | ₹1,57,368.45 Cr |
| P/B Ratio | 6.75 |
| EPS | 60.38 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 12.04 |
Divis Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,57,368.45 Cr | 44.82% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,14,215.13 Cr | 52.67% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹44,164.07 Cr | 5.12% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,248.37 Cr | -0.49% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,17,434.94 Cr | 43.08% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Divis Laboratories Ltd Mutual Fund Holdings
About Divis Laboratories Ltd
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Share Price: ₹5951.70 per share as on 12 Dec, 2024 04:01 PM
Market Capitalisation: ₹1,57,368.45Cr as of today
Revenue: ₹2,338.00Cr as on September 2024 (Q3 24)
Net Profit: ₹510.00Cr as on September 2024 (Q3 24)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Divis Laboratories Ltd
Citi Maintains Buy Rating Amid Growth Prospects - 10 Dec, 2024
Citi has reiterated its Buy rating on Divis Laboratories with a target price of ₹6,850, emphasizing strong growth potential despite delays in the BioSecure Act. The company reported a 22.5% revenue increase in Q2FY25, although shares closed slightly lower. Analysts suggest that any market corrections present buying opportunities due to a robust product pipeline.Divis Laboratories Shares Decline Amid Legislative Uncertainty - 09 Dec, 2024
Divis Laboratories shares dropped nearly 3% on December 9, 2024, following the exclusion of the US Biosecure Act from a defense bill, impacting market sentiment.Divis Laboratories Shares Drop After Court Ruling - 06 Dec, 2024
Divis Laboratories shares fell 6.2% after a US Appellate Court ruling allowed generic manufacturing of Entresto, impacting Divis' CDMO contract with Novartis. Despite the decline, management stated no material impact is expected on the company.Divis Labs Addresses Patent Ruling Concerns - 05 Dec, 2024
Divis Laboratories reassured investors about the minimal impact of a US court ruling on its operations, despite shares dropping nearly 3%. The company emphasized its ongoing supply agreements and stability in the CDMO sector.Divis Lab Reports Strong Q2 FY25 Financials - 03 Dec, 2024
Divis Laboratories Ltd reported a consolidated revenue of ₹2,444 crore for Q2 FY25, a 22.50% increase year-over-year. Profit after tax rose by 46.55% to ₹510 crore, reflecting strong financial performance. The company's market capitalization stands at ₹1,64,060 crore.Divis Laboratories Gains on Citi's Bullish Outlook - 29 Nov, 2024
Divis Laboratories shares surged following Citi's bullish report, maintaining a Buy rating with a target price of ₹6,850. Positive market reactions were fueled by a favorable US court ruling on Entresto's generic approval and strong growth prospects in the contrast media segment, leading to significant gains in market capitalization.Divis Laboratories Shares Show Modest Gains - 27 Nov, 2024
Divis Laboratories shares rose 0.04% to Rs 6074.65, with an intraday high of Rs 6123.30. The company reported consolidated sales of Rs 2444 crore for Q2 FY2024, up 11.24% from the previous quarter and 22.51% year-on-year. Net profit reached Rs 510 crore, a 46.55% increase from the same quarter last year.Divis Laboratories Shows Bullish Potential - 26 Nov, 2024
Divis Laboratories is nearing a breakout level of Rs 6,145, forming a double bottom pattern. With strong bullish indicators and significant trading volumes, upside targets of Rs 6,500 and Rs 6,600 are projected. A stop-loss at Rs 6,100 is recommended for risk management.Divis Labs Shows Indecision Amid Price Increase - 25 Nov, 2024
Divis Laboratories Ltd shares increased by 1.34% to Rs 6,080. A Spinning Top candlestick pattern suggests market indecision, with potential breakout levels at Rs 6,100 and support at Rs 6,020.Divi's Laboratories Market Cap Rises by Rs 1,806 Crore - 21 Nov, 2024
Divi's Laboratories shares increased by 1.15%, closing at Rs 5,968.75, leading to a market cap rise of Rs 1,806 crore, totaling Rs 1,58,451.56 crore. The stock's performance reflects strong investor confidence in the pharmaceutical sector.Divi's Laboratories Market Cap Rises Significantly - 19 Nov, 2024
Divi's Laboratories Limited shares increased by 2.31%, closing at Rs 5,900. This rise resulted in a market cap gain of Rs 3,534 crore, totaling Rs 1,56,626.46 crore.Divis Laboratories Stock Shows Mixed Signals - 18 Nov, 2024
Divis Laboratories Ltd. shares rose 0.19% to Rs 5755.40, with a high of Rs 5800.00. The company reported a 22.51% increase in sales year-over-year, but the MACD indicates a bearish trend. Promoters hold 51.89% stake.Divis Laboratories Reports Strong Financial Growth - 12 Nov, 2024
Divis Laboratories reported a 17% y-o-y revenue increase to Rs. 2,238 crore, with PAT rising 47% y-o-y to Rs. 510 crore. Despite slight EBITDA decline, the overall financial metrics indicate strong growth potential. Sharekhan maintains a BUY rating with a target price of Rs. 6,812.Divis Laboratories Reports Strong Q2 Results and Outlook - 11 Nov, 2024
Divis Laboratories posted a robust Q2 FY25 with a net profit of ₹510 crore, up 46.5% YoY. Revenue increased by 22.5% to ₹2,338 crore, driven by custom synthesis growth. Analysts maintain positive outlook with target price revisions, reflecting strong performance and future growth potential.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 16.16% to 17.25% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 430.0 Cr → 510.0 Cr (in ₹), with an average increase of 15.7% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 2.19K Cr → 2.44K Cr (in ₹), with an average increase of 10.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 137.9% return, outperforming this stock by 107.0%
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 64.8% return, outperforming this stock by 2.3%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 13.10% to 11.92% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, DIVISLAB stock has moved down by -2.8%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.18% to 9.80% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 51.90% to 51.89% in Sep 2024 quarter
Divis Laboratories Ltd Financials
Index Inclusions
Divis Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | ||
| Foreign Institutions | 17.25% | 6.77 | |
| Mutual Funds | 11.92% | ||
| Retail Investors | 9.8% | ||
| Others | 9.14% | 5.47 |
Divis Laboratories Ltd Key Indicators
Divis Laboratories Ltd Valuation
Divis Laboratories Ltd in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (56.82x)
December 11, 2024
Today (85.73x)
December 11, 2024
Highest (90.48x)
December 4, 2024
Divis Laboratories Ltd Earnings and Dividends
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 46.55% since last year same period to ₹510Cr in the Q2 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 18.6% jump in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Divis Laboratories Ltd has declared dividend of ₹30 - translating a dividend yield of 0.50%.
Read More about Dividends
Divis Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Divis Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Divis Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Divis Laboratories Ltd shares.
Divis Laboratories Ltd (DIVISLAB) share price today is ₹5951.7
Divis Laboratories Ltd is listed on NSE
Divis Laboratories Ltd is listed on BSE
- Today’s highest price of Divis Laboratories Ltd is ₹6055.
- Today’s lowest price of Divis Laboratories Ltd is ₹5928.25.
PE Ratio of Divis Laboratories Ltd is 85.73
PE ratio = Divis Laboratories Ltd Market price per share / Divis Laboratories Ltd Earnings per share
Today’s traded volume of Divis Laboratories Ltd(DIVISLAB) is 3.59L.
Today’s market capitalisation of Divis Laboratories Ltd(DIVISLAB) is ₹157368.45Cr.
| Divis Laboratories Ltd(DIVISLAB | Price |
|---|---|
52 Week High | ₹6285.45 |
52 Week Low | ₹3350 |
Divis Laboratories Ltd(DIVISLAB) share price is ₹5951.7. It is down -5.31% from its 52 Week High price of ₹6285.45
Divis Laboratories Ltd(DIVISLAB) share price is ₹5951.7. It is up 77.66% from its 52 Week Low price of ₹3350
| Divis Laboratories Ltd(DIVISLAB | Returns |
|---|---|
1 Day Returns | 23.75% |
1 Month Returns | 2.02% |
3 Month Returns | 8.12% |
1 Year Returns | 62.52% |